TET1 and ovarian carcinoma: Good et al. uncovered an intricate network connecting TET1 to the hypomethylation and activation of cancer-specific oncogenic pathways, including PI3K, EGFR, and PDGF, using bioinformatic analyses in both breast and ovarian cancer cell lines [21].